DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

Information source: Deva Holding A.S.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Helicobacter Pylori Infection

Intervention: Levofloxacin (Drug); Amoxicillin (Drug); Lansoprazole (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Deva Holding A.S.

Official(s) and/or principal investigator(s):
Mehmet Yucesoy, MD, Principal Investigator, Affiliation: Kayseri, Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology
Recep S Alpan, MD, PhD, MSc, Study Director, Affiliation: TNC Pharmaceuticals Research, Development and Consultancy Ltd.

Summary

Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin is expected to be 75 % or higher. If the target results can be reached, it will be concluded that TRIOL treatment with levofloxacin will be an alternative to the triple treatment with clarithromycin as the primary treatment.

Clinical Details

Official title: A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Helicobacter pylori infection eradication

Secondary outcome: Safety

Detailed description: The primary end point in this study is appointed to be "Helicobacter pylori infection eradication with TRIOL treatment" and the secondary end point as "safety". The study involves the investigation of the efficacy and safety of the triple treatment consisting of 500 mg levofloxacin, 1000 mg amoxicillin and 30 mg lansoprazole on Helicobacter pylori eradication in 60 patients with Helicobacter pylori infection.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Consenting to an endoscopy

- Signing the informed consent form

- Not receiving Helicobacter pylori eradication treatment before

- Showing Helicobacter pylori infection by rapid urease test and/or Giemsa staining

- Being older than 18 years of age

Exclusion Criteria:

- Being younger than 18 years of age

- Receiving H. pylori eradication treatment previously

- Having gastrectomy or vagotomy in medical history

- Having gastric malignancy, including adenocarcinoma and lymphoma

- Having other severe malignant disease

- Previously having allergic reaction to antibiotics (amoxicillin, levofloxacin) and

proton pump inhibitors (lansoprazole)

- Using prompt pump inhibitors (lansoprazole) and antibiotics (amoxicillin,

clarithromycin, levofloxacin) in the last 4 weeks

- Having active upper GI bleeding in the last week

- Being pregnant or lactating

- Taking long term high dosages of aspirin, corticosteroid and other NSAIDs in the last

4 weeks

- Taking any antibiotics or proton pump inhibitors other than the study medication

during the study period

- Taking antacids and/or H2-blockers during the study period

- Taking bismuth compounds within four weeks prior to and during the study period

- Having dysphasia or vomiting as major symptoms

- Having psychiatric, neurological, or behavioral disorders that may interfere with the

conduct or interpretation of the study

- Having severe concomitant disease of the cardiovascular, pulmonic, hepatic, renal,

hematological, lymphatic, metabolic, and endocrine system.

- Having known uncontrolled hypertension

- Being immunocompromised

- Showing clinically significant abnormal vital signs

- Having clinically significant abnormal ECG findings

- Presenting clinically significant abnormal laboratory data at screening, or any

abnormal laboratory value that could interfere with the assessment of safety

- Being exposed to any investigational drug within 30 days prior to screening

- Having known hypersensitivity to or contraindication against fluoroquinolones.

- Having current diagnosis or known history of substance abuse.

Locations and Contacts

Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology, Kayseri 38039, Turkey
Additional Information

Starting date: June 2010
Last updated: August 8, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017